Author:
Голубева Т.С.,Докукина Т.В.,Объедков В.Г.,Гилеп А.А.,Гайдукевич И.В.,Башко Н.П.,Бокуть О.С.,Мороз А.В.
Abstract
В обзоре литературы приведены данные о биологических маркерах, влияющих на эффективность и безопасность применения психотропных лекарственных средств при шизофрении. Оценка совокупности данных о наличии в генотипе пациента полиморфизмов генов изоферментов системы цитохрома Р450, транспортного белка Р-гликопротеина, молекул – мишеней психотропных лекарственных средств и функционально связанных с ними белков, а также данных о «метаболическом фенотипе» пациента может быть полезна при выборе тактики лечения.
The literature review provides data on biological markers that affect the efficacy and safety of psychotropic drugs in schizophrenia. Assessment of the data on the presence of polymorphisms of genes of isoenzymes of the cytochrome P450 system, P-glycoprotein transport protein, target molecules of psychotropic drugs, and proteins functionally associated with them in the patient’s genotype, as well as the data on the patient’s “metabolic phenotype” can be useful in choosing the tactics of treatment.
Publisher
Professionals Publications
Subject
Psychiatry and Mental health,Clinical Psychology
Reference51 articles.
1. Sychev D. (2011) Pharmacogenetic Testing: Clinical Interpretation of Results: Guidelines for Practitioners. M, 89 p.
2. Belenichev I., Bukhtiyarova N., Pavlov S. (2018) Pharmacokinetic monitoring of drugs. Textbook for masters of the specialty: 224. Technologies of medical diagnostics and treatment and for students of the specialty 7.12020101. Pharmacy, Zaporozh’ye, 94 p.
3. Miiller D., Brandl E., Hwang R. (2012) The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genet. Test Mol. Biomarkers, vol. 8, no 16, pp. 897–903.
4. Fleeman N., Dundar Y., Dickson R. (2011) Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta- analyses. Pharmacogenomics J., vol. 1, no 11, pp. 1–14.
5. Winner J., Carhart J., Altar C. (2013) A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov. Med, vol. 89, no 16, pp. 219–227.